TapImmune Inc.
2815 Eastlake Avenue East
Suite 300
Seattle
Washington
98102
United States
Tel: 866-359-7541
Website: http://www.tapimmune.com/
Email: ir@TapImmune.com
161 articles about TapImmune Inc.
-
TapImmune Inc. Executes a Securities Purchase Agreement for the Issuance of $1.53 Million in Convertible Debt
5/18/2010
-
TapImmune Inc. Provides Shareholder Letter
2/23/2010
-
TapImmune Inc. Signs R&D Collaboration Letter of Intent Agreement With Aeras Global TB Vaccine Foundation
2/1/2010
-
TapImmune Inc. Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Counsel
1/12/2010
-
TapImmune Inc. to Present at OneMedPlace Forum 2010
1/11/2010
-
TapImmune Inc. Signs License Agreement With Crucell N.V.
11/5/2009
-
TapImmune Inc. Signs License Agreement With Crucell N.V.
11/4/2009
-
TapImmune Inc. Receives BUY Recommendation From the KonLin
10/7/2009
-
TapImmune Inc. Provides Shareholder Update
10/1/2009
-
TapImmune Inc. Announces Corporate Restructuring
6/30/2009
-
TapImmune Inc. Issued U.S. Patent Relating to Methods for Enhancing an Immune Response
6/30/2008
-
TapImmune Inc. Announces Execution of Exclusive Option Agreement With The University of British Columbia
6/9/2008
-
TapImmune Inc. Provides Shareholder Update and Review; Company Announces Completion of Initial Sterility Testing
4/21/2008
-
TapImmune Inc. Receives Notice of Allowance for U.S. Patent Relating to Methods for Enhancing an Immune Response
1/22/2008
-
TapImmune Inc. Retains ROI Group as Investor Relations Counsel
1/16/2008
-
TapImmune Inc. Announces Granting of U.S. Pat. Appln No. 10/046,542 Petition to Revive and Secure Bridge Financing
12/6/2007
-
TapImmune Inc. Announces Agreement With AppTec
8/16/2007
-
TapImmune Inc. Provides Operational Update Including Human Data Supporting Use of TAP-Based Cancer Vaccine
8/1/2007
-
TapImmune Inc. Announces Availability of New Investor Information
7/17/2007
-
TapImmune Inc. CEO Featured in Exclusive Interview
7/6/2007